Airbus Signs Cloud Deal With Scaleway to Power Secure AI and Defense Applications 
BHP Q4 Iron Ore Output Rebounds as Copper Prices Boost Revenue 
Stripe, Advent Offer Over $53 Billion to Acquire PayPal in Major Fintech Deal 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
Hyundai Takes Full Control of Boston Dynamics to Accelerate Humanoid Robot and AI Strategy 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
UBS Boosts China Tech Bets, Adds Kuaishou and Meituan to Focus List 
Sodexo Unveils Shift & Grow 2030 Strategy, Targets Over 5% Revenue Growth by Fiscal 2030 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
BOSTON, Jan. 27, 2016 -- Topokine Therapeutics, the biotechnology company pioneering topical medications to contour the face and body, announced today that it has initiated a Phase 2 study of TAT4 Gel for reduction of nasolabial folds. Commonly known as laugh lines, nasolabial folds are a common sign of aging. They are typically treated with injectable dermal fillers.
TAT4 Gel is the second product in Topokine’s innovative pipeline of topical adipomodulatory medicines. Applied to the skin once daily, TAT4 acts pharmacologically to increase subcutaneous fat, thereby softening skin wrinkles and folds. As part of the randomized, placebo-controlled trial, patients are applying TAT4 Gel to their nasolabial folds for three months.
“Our faces lose volume as we age, which deepens nasolabial folds,” said Jody Levine, MD, FAAD, FAAP, a New York dermatologist recognized by New Beauty as one of the nation’s Top Beauty Doctors. “TAT4 was designed to enhance tissue volume by increasing subcutaneous fat.”
“Today, many patients and dermatologists rely on injectable dermal fillers to rejuvenate the skin,” said Michael Singer, MD, PhD, Topokine’s Chief Scientific Officer. “TAT4 is based on a simple concept—that instead of injecting foreign substances into the skin, a topical product can signal the patient’s own cells to reestablish a more youthful contour.”
About Topokine
Topokine is a clinical-stage biotechnology company developing topical prescription medications that act pharmacologically on adipocytes to contour the face and body. The company’s lead program, XAF5 Ointment, is in late-stage clinical development for reduction of undereye bags (steatoblepharon). Topokine’s pipeline also includes TAT4 Gel, which increases subcutaneous fat and is in Phase 2 development as a “topical filler” for reduction of laugh lines (nasolabial folds). The company’s assets are protected by over 75 issued and pending patents worldwide. For more information, visit www.topokine.com.
Contact: Matt Burke [email protected]
